Zeaxanthin
Zeaxanthin
TL;DR
Zeaxanthin is the carotenoid that concentrates in the very centre of the macula, where lutein does not dominate. At 2-4 mg/day alongside 10 mg lutein it raises macular pigment optical density and, in AREDS2, contributed to reduced progression to advanced AMD in people with low dietary intake.
Ideal For
- Adults with intermediate AMD following AREDS2 supplementation
- People with low dietary intake of orange and yellow vegetables
- Adults with heavy screen exposure reporting glare and slow dark adaptation
- Anyone who previously took beta-carotene formulas and smokes or formerly smoked
Avoid If
- You expect it to reverse existing macular damage
- You have wet AMD and are considering it instead of anti-VEGF therapy
- You have undiagnosed vision change that has not been examined
- You are taking high-dose beta-carotene, which competes for absorption
Frequently Asked Questions
Overview
The macula filters blue light using three carotenoids: lutein at the periphery, zeaxanthin in the mid-region and meso-zeaxanthin at the fovea itself. Zeaxanthin is the one most people underconsume, since dietary sources — orange peppers, goji berries, corn, egg yolk — are narrower than the leafy greens that supply lutein. AREDS2 tested 10 mg lutein with 2 mg zeaxanthin and found the pair was a safe substitute for beta-carotene, with the clearest benefit in participants in the lowest quintile of dietary intake, where progression to advanced AMD fell meaningfully. Separately, supplementation reliably raises macular pigment optical density over three to six months, and several trials report improved contrast sensitivity and glare recovery in healthy adults with visually demanding work. What zeaxanthin does not do is restore vision already lost or replace intravitreal therapy in wet AMD. The practical question is rarely zeaxanthin alone but whether a product supplies it at AREDS2 ratios rather than as a token inclusion.
How It Works
- Deposits in the central fovea, the region of highest photoreceptor density
- Absorbs short-wavelength blue light before it reaches photoreceptor outer segments
- Quenches singlet oxygen and peroxyl radicals in a high-oxygen-tension tissue
- Raises macular pigment optical density, measurable within 12 weeks
- Reduces disability glare and shortens photostress recovery time
- Partially isomerises to meso-zeaxanthin in the retina
Quick Facts
- Concentrated in central macula
- Protects against blue light damage
- Supports sharp central vision
- Works synergistically with lutein
- Reduces AMD risk
Health Concerns Addressed
No linked health concerns yet.
Supporting Research17 studies
Effects of a Lutein and Zeaxanthin Intervention on Cognitive Function: A Randomized, Double-Masked, Placebo-Controlled Trial of Younger Healthy Adults
Renzi-Hammond LM, Bovier ER, Fletcher LM
One year of lutein and zeaxanthin improved macular pigment and some measures of processing speed in young healthy adults.
Macular Pigment and Percentage of Body Fat
Nolan JM, Loskutova E, Howard AN +11 more
Macular pigment optical density was inversely related to percentage body fat, consistent with sequestration of lutein and zeaxanthin in adipose tissue reducing retinal availability. Supplementation raised macular pigment even in participants with higher body fat, though response varied.
Lutein and zeaxanthin for the prevention of age-related cataract
Mathew MC, Ervin AM, Tao J +1 more
There is no evidence from randomised trials that antioxidant vitamin or carotenoid supplementation prevents or slows age-related cataract.
Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4
Chew EY, SanGiovanni JP, Ferris FL +2 more
Participants were randomly assigned to daily placebo; lutein/zeaxanthin, 10mg/2mg; omega-3 long-chain polyunsaturated fatty acids, 1 g; or a combination.
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
Age-Related Eye Disease Study 2 Research Group, Chew EY, Clemons TE +8 more
Lutein plus zeaxanthin did not significantly reduce progression to advanced AMD overall, but was a suitable and safer replacement for beta-carotene in the AREDS formulation.
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
Adding lutein and zeaxanthin to the AREDS formulation did not further reduce progression to advanced AMD overall.
Lutein and zeaxanthin supplementation and association with visual function in age-related macular degeneration
Liu R, Wang T, Zhang B
Zeaxanthin with lutein improved macular pigment density and contrast sensitivity dose-dependently.
Lutein and zeaxanthin supplementation and association with visual function in age-related macular degeneration: a meta-analysis
Liu R, Wang T, Zhang B
Zeaxanthin with lutein improved macular pigment density and contrast sensitivity dose-dependently.
Lutein and zeaxanthin supplementation and association with visual function in age-related macular degeneration
Liu R, Wang T, Zhang B +4 more
Supplementation increased macular pigment optical density in a dose-dependent manner and improved best-corrected visual acuity and contrast sensitivity in AMD patients.
Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28
Long-term follow-up favoured lutein/zeaxanthin over beta-carotene for AMD progression and safety.
Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3
AREDS2 Research Group, Chew EY, Clemons TE
In secondary analyses, lutein/zeaxanthin was associated with reduced progression to advanced AMD compared with beta-carotene, particularly in participants with low dietary intake.
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
Lutein/zeaxanthin-containing supplements slowed central geographic atrophy progression.
Effect of supplementation with lutein, zeaxanthin, and omega-3 fatty acids on macular pigment and visual function in young adults with long-term use of digital devices: study protocol for a randomized double-blind placebo-controlled study
Wang L, Ma M, Li Y +3 more
Current trial evidence on lutein bioavailability is contradictory
Lutein and zeaxanthin intake and the risk of age-related macular degeneration: a systematic review and meta-analysis
Ma L, Dou HL, Wu YQ +5 more
Higher dietary lutein and zeaxanthin intake was associated with a 26% lower risk of late age-related macular degeneration but not early AMD.
Macular carotenoid supplementation improves visual performance, sleep quality, and adverse physical symptoms in those with high screen time exposure
Stringham JM, Stringham NT, O'Brien KJ
Macular pigment optical density, contrast sensitivity and photostress recovery improved, and headache frequency and eye strain decreased versus placebo.
Effects of lutein/zeaxanthin supplementation on the cognitive function of community dwelling older adults: a randomized, double-masked, placebo-controlled trial
Hammond BR, Miller LS, Bello MO +3 more
Supplemented older adults showed improved complex attention and cognitive flexibility relative to placebo.
Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial
Chew EY, Clemons TE, Agron E
Lutein/zeaxanthin supplementation had no statistically significant effect on cognitive function over five years in AREDS2 participants.
Safety Information
Potential Side Effects
Very well tolerated. High long-term intakes can cause harmless yellowing of the skin (carotenodermia). No serious adverse events were attributed to lutein or zeaxanthin across five years of AREDS2 follow-up.
Contraindications
None established at supplemental doses. Undiagnosed vision loss requires ophthalmic assessment first.
Drug Interactions
- Orlistat and other fat-absorption blockers substantially reduce carotenoid uptake
- Bile acid sequestrants reduce absorption — separate dosing
- High-dose beta-carotene competes for the same absorption pathways
Pregnancy & Breastfeeding
Pregnancy: likely_safe
Breastfeeding: likely_safe
Dosage Guidelines
Dosage Used in Studies
2-4 mg
Best Time to Take
Once daily with the main meal
Best Form
Free (non-esterified) zeaxanthin at 2 mg paired with 10 mg lutein
Bioavailability
Fat-dependent and matrix-dependent. Free zeaxanthin is absorbed more predictably than esters, and co-ingestion with 5-10 g of dietary fat markedly increases plasma response.
Forms Compared
Free zeaxanthin (FloraGLO/OPTISHARP type)
Zeaxanthin esters from goji or paprika
Meso-zeaxanthin blends
AREDS2 formula
Whole-food sources
Food & Timing
With a meal containing fat — carotenoid absorption is several-fold lower on an empty stomach
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.